Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in oncology and CNS, today announced that it will present at the Stifel Nicolaus Healthcare Conference on September 5, 2012, at 9:10 AM Eastern Time at the Four Seasons Hotel in Boston, MA. Rexahn’s President and Chief Operating Officer, Rick Soni, and Chief Financial Officer, Ted Jeong, will provide a strategic business overview of the Company, including a discussion of its R&D pipeline. About Rexahn Pharmaceuticals, Inc. Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit www.rexahn.com.